<!DOCTYPE html>
<html lang="en">

<head>
	<meta charset="utf-8">
	<meta name="viewport" content="width=device-width, initial-scale=1.0">
    <!--	boostrap-->
	<link rel="stylesheet" href="https://stackpath.bootstrapcdn.com/bootstrap/4.5.0/css/bootstrap.min.css" integrity="sha384-9aIt2nRpC12Uk9gS9baDl411NQApFmC26EwAOH8WgZl5MYYxFfc+NcPb1dKGj7Sk" crossorigin="anonymous">
	
    <!--	custom css-->
    <link rel="stylesheet" href="css/vaccine.css">
    
    <!--	favicon-->
    <link rel="icon" type="image/png" href="images/favicon-32x32.png">
	
	
	<title>Minimum Bootstrap HTML Skeleton</title>

	<!--  -->

	<style>

	</style>

</head>

<body>
        
        <main>
        <h1 class="covid"> Covid - 19 </h1>
        <h1 class="track">VACCINE TRACKER</h1>
        <p class="rea">Researchers around the world are working on more than 150 vaccines to combat coronavirus. <br> Here are some of top contenders in various stages of development, including two Indian companies - Zydus Cadiala and Bharat Biotech. </p>
        <h5 class="track"> As of July 25, 2020. </h5>
        <div class="content" style="margin-top: 10vh;">
        
        <!--Progress 1-->
            <div class="row">
                <div class="col-4">
                <div class="row">
                    <div class="col-4"></div>
                    <div class="col-8"> 
                    <p class="name"> Wuhan Institute / Sinophram </p> 
                    </div>
                </div>
                </div>
                <div class="col-8"> 
                 <div class="row">
                 <div class="col-9">
                <div class="progress">
                  <div class="progress-bar bg-danger" role="progressbar" style="width: 20%" aria-valuenow="15" aria-valuemin="0" aria-valuemax="100">Clinical</div>
                  <div class="progress-bar bg-info" role="progressbar" style="width: 20%" aria-valuenow="30" aria-valuemin="0" aria-valuemax="100">Phase I</div>
                  <div class="progress-bar bg-warning" role="progressbar" style="width: 20%" aria-valuenow="20" aria-valuemin="0" aria-valuemax="100">Phase II</div>                  
                  <div class="progress-bar bg-light" role="progressbar" style="width: 20%" aria-valuenow="20" aria-valuemin="0" aria-valuemax="100"></div>                  
                  <div class="progress-bar bg-light" role="progressbar" style="width: 20%" aria-valuenow="20" aria-valuemin="0" aria-valuemax="100"></div>
                  <br> 
                </div>
                </div>
                  <div class="col-3"></div>
                </div>
                </div>
            </div>
            
            <!--Content1-->
            
            <div style="text-align: center;">
            <p>
                  <button class="btn btn-primary" type="button" data-toggle="collapse" data-target="#collapseExample1" aria-expanded="false" aria-controls="collapseExample">More info!
                  </button>
                    <a href="http://www.wibp.com.cn/ChsMobile/Default.aspx" class="btn btn-warning">Take me there!</a>  
            </p>
            <div class="collapse" id="collapseExample1">
              <div class="card card-body" style="background-color: #13a5e4; color:white;">
                Background: Researchers at Sinopharm and the Wuhan Institute of Virology under the Chinese Academy of Sciences are developing an inactivated COVID-19 vaccine candidate. They have initiated a randomized, double-blind, placebo parallel-controlled Phase 1/2 clinical trial (ChiCTR2000031809) of healthy individuals starting at 6 years old.
                <br>
                Outcomes: The vaccine has shown a "strong neutralizing antibody response" in Phase 1/2 trials, according to a release from China National Biotec Group.
                <br>
                Status: A Phase 3 trial is underway conducted in the United Arab Emirates.
              </div>
            </div>
            </div>
                   
                   
            <!--Progress2-->
            <div class="row" style="margin-top: 10vh;">
                <div class="col-4">
                <div class="row">
                    <div class="col-4"></div>
                    <div class="col-8"> 
                    <p class="name"> Sinovac / Instituto Butantan </p> 
                    </div>
                </div>
                </div>
                <div class="col-8"> 
                 <div class="row">
                 <div class="col-9">
                <div class="progress">
                  <div class="progress-bar bg-danger" role="progressbar" style="width: 20%" aria-valuenow="15" aria-valuemin="0" aria-valuemax="100">Clinical</div>
                  <div class="progress-bar bg-info" role="progressbar" style="width: 20%" aria-valuenow="30" aria-valuemin="0" aria-valuemax="100">Phase I</div>
                  <div class="progress-bar bg-warning" role="progressbar" style="width: 20%" aria-valuenow="20" aria-valuemin="0" aria-valuemax="100">Phase II</div>                  
                  <div class="progress-bar bg-primary" role="progressbar" style="width: 20%" aria-valuenow="20" aria-valuemin="0" aria-valuemax="100">Phase III</div>                  
                  <div class="progress-bar bg-light" role="progressbar" style="width: 20%" aria-valuenow="20" aria-valuemin="0" aria-valuemax="100"></div>
                </div>
                </div>
                  <div class="col-3"></div>
                </div>
                </div>
            </div>
            
            <!--            Content2-->
            
            <div style="text-align: center;">
            <p>
                  <button class="btn btn-primary" type="button" data-toggle="collapse" data-target="#collapseExample2" aria-expanded="false" aria-controls="collapseExample">More info!
                  </button>
                    <a href="http://www.sinovac.com/" class="btn btn-warning">Take me there!</a>  
            </p>
            <div class="collapse" id="collapseExample2">
              <div class="card card-body" style="background-color: #13a5e4; color:white;">
                Background: CoronaVac (formerly PiCoVacc) is a formalin-inactivated and alum-adjuvanted candidate vaccine. Results from animal studies showed “partial or complete protection in macaques” exposed to SARS-CoV-2, according to a paper published by researchers in the journal Science. <br>
                Outcomes: Results from the Phase 1/2 trials showed no serious adverse events, the company said in a press release. Neutralizing antibodies were observed 14 days after vaccine administration, and the company reported a greater than 90% neutralizing antibody seroconversion rate, indicating a positive immune response. <br>
                Status: Sinovac said a Phase 3 trial in collaboration with Instituto Butantan in Brazil is underway, and the company plans to enroll around 9,000 patients in the healthcare industry.
              </div>
            </div>
            </div>
            
            
             <!--Progress3-->
            <div class="row" style="margin-top: 10vh;">
                <div class="col-4">
                <div class="row">
                    <div class="col-4"></div>
                    <div class="col-8"> 
                    <p class="name"> Beijing Institute of biotech.</p> 
                    </div>
                </div>
                </div>
                <div class="col-8"> 
                 <div class="row">
                 <div class="col-9">
                <div class="progress">
                  <div class="progress-bar bg-danger" role="progressbar" style="width: 20%" aria-valuenow="15" aria-valuemin="0" aria-valuemax="100">Clinical</div>
                  <div class="progress-bar bg-info" role="progressbar" style="width: 20%" aria-valuenow="30" aria-valuemin="0" aria-valuemax="100">Phase I</div>
                  <div class="progress-bar bg-warning" role="progressbar" style="width: 20%" aria-valuenow="20" aria-valuemin="0" aria-valuemax="100">Phase II</div>                  
                  <div class="progress-bar bg-primary" role="progressbar" style="width: 20%" aria-valuenow="20" aria-valuemin="0" aria-valuemax="100">Phase III</div>                  
                  <div class="progress-bar bg-success" role="progressbar" style="width: 20%" aria-valuenow="20" aria-valuemin="0" aria-valuemax="100">Approved</div>
                </div>
                </div>
                  <div class="col-3"></div>
                </div>
                </div>
            </div>
            
            <!--            Content3-->
            
            <div style="text-align: center;">
            <p>
                  <button class="btn btn-primary" type="button" data-toggle="collapse" data-target="#collapseExample3" aria-expanded="false" aria-controls="collapseExample">More info!
                  </button>
                    <a href="http://www.sinopharm.com/1156.html" class="btn btn-warning">Take me there!</a>  
            </p>
            <div class="collapse" id="collapseExample3">
              <div class="card card-body" style="background-color: #13a5e4; color:white;">
            Background: Sinopharm is developing a second inactivated COVID-19 vaccine candidate, BBIBP-CorV, with the Beijing Institute of Biological Products. BBIBP-CorV is currently being evaluated in a Phase 2 trial (ChiCTR2000032459). <br>

            Outcomes: Results from a paper published in the journal Cell appear to show BBIBP-CorV provides "highly efficient protection" against SARS-CoV-2 in rhesus macaques who underwent challenge against the virus. <br>

            Status: More than 2,000 vaccines administered between Sinopharm's two inactivated vaccine trials. Both vaccine candidates could be ready for market by the end of the year, according to reporting from Reuters. <br>
              </div>
            </div>
            </div>
                  
                                <!--Progress4-->
            <div class="row" style="margin-top: 10vh;">
                <div class="col-4">
                <div class="row">
                    <div class="col-4"></div>
                    <div class="col-8"> 
                    <p class="name">Sinophram</p> 
                    </div>
                </div>
                </div>
                <div class="col-8"> 
                 <div class="row">
                 <div class="col-9">
                <div class="progress">
                  <div class="progress-bar bg-danger" role="progressbar" style="width: 20%" aria-valuenow="15" aria-valuemin="0" aria-valuemax="100">Clinical</div>
                  <div class="progress-bar bg-info" role="progressbar" style="width: 20%" aria-valuenow="30" aria-valuemin="0" aria-valuemax="100">Phase I</div>
                  <div class="progress-bar bg-warning" role="progressbar" style="width: 20%" aria-valuenow="20" aria-valuemin="0" aria-valuemax="100">Phase II</div>                  
                  <div class="progress-bar bg-light" role="progressbar" style="width: 20%" aria-valuenow="20" aria-valuemin="0" aria-valuemax="100"></div>                  
                  <div class="progress-bar bg-light" role="progressbar" style="width: 20%" aria-valuenow="20" aria-valuemin="0" aria-valuemax="100"></div>
                </div>
                </div>
                  <div class="col-3"></div>
                </div>
                </div>
            </div>
            
            <!--            Content4-->
            
            <div style="text-align: center;">
            <p>
                  <button class="btn btn-primary" type="button" data-toggle="collapse" data-target="#collapseExample4" aria-expanded="false" aria-controls="collapseExample">More info!
                  </button>
                    <a href="http://www.sinopharm.com/1156.html" class="btn btn-warning">Take me there!</a>  
            </p>
            <div class="collapse" id="collapseExample4">
              <div class="card card-body" style="background-color: #13a5e4; color:white;">
                Background: Researchers at Sinopharm and the Wuhan Institute of Virology under the Chinese Academy of Sciences are developing an inactivated COVID-19 vaccine candidate. They have initiated a randomized, double-blind, placebo parallel-controlled Phase 1/2 clinical trial (ChiCTR2000031809) of healthy individuals starting at 6 years old. <br>

                Outcomes: The vaccine has shown a "strong neutralizing antibody response" in Phase 1/2 trials, according to a release from China National Biotec Group. <br>

                Status: A Phase 3 trial is underway conducted in the United Arab Emirates. <br>
                
              </div>
            </div>
            </div>
            
                <!--Progress5-->
            <div class="row" style="margin-top: 10vh;">
                <div class="col-4">
                <div class="row">
                    <div class="col-4"></div>
                    <div class="col-8"> 
                    <p class="name"> Novavax </p> 
                    </div>
                </div>
                </div>
                <div class="col-8"> 
                 <div class="row">
                 <div class="col-9">
                <div class="progress">
                  <div class="progress-bar bg-danger" role="progressbar" style="width: 20%" aria-valuenow="15" aria-valuemin="0" aria-valuemax="100">Clinical</div>
                  <div class="progress-bar bg-info" role="progressbar" style="width: 20%" aria-valuenow="30" aria-valuemin="0" aria-valuemax="100">Phase I</div>
                  <div class="progress-bar bg-warning" role="progressbar" style="width: 20%" aria-valuenow="20" aria-valuemin="0" aria-valuemax="100">Phase II</div>                  
                  <div class="progress-bar bg-light" role="progressbar" style="width: 20%" aria-valuenow="20" aria-valuemin="0" aria-valuemax="100"></div>                  
                  <div class="progress-bar bg-light" role="progressbar" style="width: 20%" aria-valuenow="20" aria-valuemin="0" aria-valuemax="100"></div>
                </div>
                </div>
                  <div class="col-3"></div>
                </div>
                </div>
            </div>
            
            <!--            Content5-->
            
            <div style="text-align: center;">
            <p>
                  <button class="btn btn-primary" type="button" data-toggle="collapse" data-target="#collapseExample5" aria-expanded="false" aria-controls="collapseExample">More info!
                  </button>
                    <a href="https://novavax.com/" class="btn btn-warning">Take me there!</a>  
            </p>
            <div class="collapse" id="collapseExample5">
              <div class="card card-body" style="background-color: #13a5e4; color:white;">
            Background: Biotech company Novavax announced in March that it has produced a stable, prefusion protein nanoparticle vaccine candidate for COVID-19. A Phase 1/2 trial evaluating NVX-CoV2373 began on 25 May. <br>

            Study Design: A randomized, observer-blinded, placebo-controlled trial of 130 healthy participants 18 to 59 years of age at two sites in Australia is being conducted. Patients will receive a two-dose regimen of 5 μg or 25 μg of NVX-CoV2373 with or without Novavax's Matrix‑M adjutant (NCT04368988). <br>

            Status: On May 11, CEPI announced they had provided Novavax with an additional $384 million towards the development and manufacturing of NVX-CoV2373. Novavax plans to manufacture 1 billion doses of NVX-CoV2373 by 2021 as part of their recent acquision of Praha Vaccines. 
              </div>
            </div>
            </div>
            
                <!--Progress6-->
            <div class="row" style="margin-top: 10vh;">
                <div class="col-4">
                <div class="row">
                    <div class="col-4"></div>
                    <div class="col-8"> 
                    <p class="name"> Moderna</p> 
                    </div>
                </div>
                </div>
                <div class="col-8"> 
                 <div class="row">
                 <div class="col-9">
                <div class="progress">
                  <div class="progress-bar bg-danger" role="progressbar" style="width: 20%" aria-valuenow="15" aria-valuemin="0" aria-valuemax="100">Clinical</div>
                  <div class="progress-bar bg-info" role="progressbar" style="width: 20%" aria-valuenow="30" aria-valuemin="0" aria-valuemax="100">Phase I</div>
                  <div class="progress-bar bg-warning" role="progressbar" style="width: 20%" aria-valuenow="20" aria-valuemin="0" aria-valuemax="100">Phase II</div>                  
                  <div class="progress-bar bg-light" role="progressbar" style="width: 20%" aria-valuenow="20" aria-valuemin="0" aria-valuemax="100"></div>                  
                  <div class="progress-bar bg-light" role="progressbar" style="width: 20%" aria-valuenow="20" aria-valuemin="0" aria-valuemax="100"></div>
                </div>
                </div>
                  <div class="col-3"></div>
                </div>
                </div>
            </div>
            
            <!--            Content6-->
            
            <div style="text-align: center;">
            <p>
                  <button class="btn btn-primary" type="button" data-toggle="collapse" data-target="#collapseExample6" aria-expanded="false" aria-controls="collapseExample">More info!
                  </button>
                    <a href="https://www.modernatx.com/" class="btn btn-warning">Take me there!</a>  
            </p>
            <div class="collapse" id="collapseExample6">
              <div class="card card-body" style="background-color: #13a5e4; color:white;">
            Background: mRNA-1273 was developed by Moderna based on prior studies of related coronaviruses such as those that cause severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS). A Phase 1 trial (NCT04283461) of 105 healthy participants provided the basis for Moderna’s investigational new drug application (IND), which was successfully reviewed by the FDA and set the stage for Phase 2 testing. A Phase 2 trial of 600 healthy participants evaluating 25 µg, 100 µg, and 250 µg dose levels of the vaccine was completed, and mRNA-1273 has advanced to a Phase 3 trial (NCT04405076). <br>

            Study Design: A Phase 3 trial of 30,000 participants at high risk for SARS-CoV-2 infection who will receive a 100 µg dose of mRNA-1273 or placebo and then followed for up to 2 years (COVE trial; NCT04470427). <br>

            Outcomes: Phase 1 data published in the New England Journal of Medicine showed mRNA-1273 successfully produced neutralizing antibody titers in 8 participants who received either 25 µg or 100 µg doses. The response was dose dependent in 45 participants across 25 µg, 100 µg, and 250 µg dose levels. 
              </div>
            </div>
            </div>
            
                                      <!--Progress7-->
            <div class="row" style="margin-top: 10vh;">
                <div class="col-4">
                <div class="row">
                    <div class="col-4"></div>
                    <div class="col-8"> 
                    <p class="name"> BioNTech</p> 
                    </div>
                </div>
                </div>
                <div class="col-8"> 
                 <div class="row">
                 <div class="col-9">
                <div class="progress">
                  <div class="progress-bar bg-danger" role="progressbar" style="width: 20%" aria-valuenow="15" aria-valuemin="0" aria-valuemax="100">Clinical</div>
                  <div class="progress-bar bg-info" role="progressbar" style="width: 20%" aria-valuenow="30" aria-valuemin="0" aria-valuemax="100">Phase I</div>
                  <div class="progress-bar bg-warning" role="progressbar" style="width: 20%" aria-valuenow="20" aria-valuemin="0" aria-valuemax="100">Phase II</div>                  
                  <div class="progress-bar bg-light" role="progressbar" style="width: 20%" aria-valuenow="20" aria-valuemin="0" aria-valuemax="100"></div>                  
                  <div class="progress-bar bg-light" role="progressbar" style="width: 20%" aria-valuenow="20" aria-valuemin="0" aria-valuemax="100"></div>
                </div>
                </div>
                  <div class="col-3"></div>
                </div>
                </div>
            </div>
            
            <!--            Content7-->
            
            <div style="text-align: center;">
            <p>
                  <button class="btn btn-primary" type="button" data-toggle="collapse" data-target="#collapseExample7" aria-expanded="false" aria-controls="collapseExample">More info!
                  </button>
                    <a href="https://biontech.de/" class="btn btn-warning">Take me there!</a>  
            </p>
            <div class="collapse" id="collapseExample7">
              <div class="card card-body" style="background-color: #13a5e4; color:white;">
            Background: Pfizer and BioNtech are collaborating BNT162, a series of vaccine candidates for COVID-19. BNT162 was initially four vaccine candidates originally developed by BioNTech, two candidates consisting of nucleoside modified mRNA-based (modRNA), one of uridine containing mRNA-based (uRNA), and the fourth candidate of self-amplifying mRNA-based (saRNA). The companies have selected the modRNA candidate BNT162b2 to move forward in a Phase 2/3 trial. <br>
             
             Outcomes: Results of one study of BNT162b1, a modRNA candidate, were reported 1 July on the non-peer-reviewed preprint server medRxiv. Robust immunogenicity was seen after vaccination at all three doses (10 μg, 30 μg and 100 μg). Adverse events were elevated at the highest dose; therefore, participants did not receive a second dose at that level. <br>

            Status: Pfizer and BioNTech received FDA Fast Track designation for two of the BNT162 candidates, BNT162b1 and BNT162b2. The companies have published results from a study that suggests one of the BNT162 candidates, BNT162b1, produced a neutralizing antibody response in participants who received the vaccine.
              </div>
            </div>
            </div>
            
                                      <!--Progress8-->
            <div class="row" style="margin-top: 10vh;">
                <div class="col-4">
                <div class="row">
                    <div class="col-4"></div>
                    <div class="col-8"> 
                    <p class="name"> Imperial College of London</p> 
                    </div>
                </div>
                </div>
                <div class="col-8"> 
                 <div class="row">
                 <div class="col-9">
                <div class="progress">
                  <div class="progress-bar bg-danger" role="progressbar" style="width: 20%" aria-valuenow="15" aria-valuemin="0" aria-valuemax="100">Clinical</div>
                  <div class="progress-bar bg-info" role="progressbar" style="width: 20%" aria-valuenow="30" aria-valuemin="0" aria-valuemax="100">Phase I</div>
                  <div class="progress-bar bg-warning" role="progressbar" style="width: 20%" aria-valuenow="20" aria-valuemin="0" aria-valuemax="100">Phase II</div>                  
                  <div class="progress-bar bg-light" role="progressbar" style="width: 20%" aria-valuenow="20" aria-valuemin="0" aria-valuemax="100"></div>                  
                  <div class="progress-bar bg-light" role="progressbar" style="width: 20%" aria-valuenow="20" aria-valuemin="0" aria-valuemax="100"></div>
                </div>
                </div>
                  <div class="col-3"></div>
                </div>
                </div>
            </div>
            
            <!--            Content8-->
            
            <div style="text-align: center;">
            <p>
                  <button class="btn btn-primary" type="button" data-toggle="collapse" data-target="#collapseExample8" aria-expanded="false" aria-controls="collapseExample">More info!
                  </button>
                    <a href="https://www.imperial.ac.uk/" class="btn btn-warning">Take me there!</a>  
            </p>
            <div class="collapse" id="collapseExample8">
              <div class="card card-body" style="background-color: #13a5e4; color:white;">
              Background: Imperial College London researchers are developing a self-amplifying RNA vaccine for COVID-19. They developed a vaccine candidate within 14 days of receiving the sequence from China. Animal testing is underway. The investigators have received two rounds of funding from the United Kingdom’s government – one on 22 April and another on 17 May. <br>

              Study Design: The Phase 1/2 COVAC1 trial will enroll approximately 300 healthy participants between 18 and 75 years old, with an efficacy trial for 6,000 participants planned for October. <br>

              Status: On 7 June, Imperial College London announced it had partnered with Morningside Ventures to establish VacEquity Global Health, an initiative that would help keep costs down for their COVID-19 vaccines down for citizens in the UK and internationally.
              </div>
            </div>
            </div>
            
                                      <!--Progress9-->
            <div class="row" style="margin-top: 10vh;">
                <div class="col-4">
                <div class="row">
                    <div class="col-4"></div>
                    <div class="col-8"> 
                    <p class="name"> Oxford University</p> 
                    </div>
                </div>
                </div>
                <div class="col-8"> 
                 <div class="row">
                 <div class="col-9">
                <div class="progress">
                  <div class="progress-bar bg-danger" role="progressbar" style="width: 20%" aria-valuenow="15" aria-valuemin="0" aria-valuemax="100">Clinical</div>
                  <div class="progress-bar bg-info" role="progressbar" style="width: 20%" aria-valuenow="30" aria-valuemin="0" aria-valuemax="100">Phase I</div>
                  <div class="progress-bar bg-warning" role="progressbar" style="width: 20%" aria-valuenow="20" aria-valuemin="0" aria-valuemax="100">Phase II</div>                  
                  <div class="progress-bar bg-primary" role="progressbar" style="width: 20%" aria-valuenow="20" aria-valuemin="0" aria-valuemax="100">Phase III</div>                  
                  <div class="progress-bar bg-light" role="progressbar" style="width: 20%" aria-valuenow="20" aria-valuemin="0" aria-valuemax="100"></div>
                </div>
                </div>
                  <div class="col-3"></div>
                </div>
                </div>
            </div>
            
            <!--            Content9-->
            
            <div style="text-align: center;">
            <p>
                  <button class="btn btn-primary" type="button" data-toggle="collapse" data-target="#collapseExample9" aria-expanded="false" aria-controls="collapseExample">More info!
                  </button>
                    <a href="https://www.ovg.ox.ac.uk/" class="btn btn-warning">Take me there!</a>  
            </p>
            <div class="collapse" id="collapseExample9">
              <div class="card card-body" style="background-color: #13a5e4; color:white;">
              Background: The Oxford Vaccine Group at the University of Oxford are developing a new vaccine candidate for COVID-19, a chimpanzee adenovirus vaccine vector called AZD1222 (previously ChAdOx1). The team has previously developed a MERS vaccine. Preclinical data in a paper on the pre-print server bioRxiv that showed a significantly reduced viral load and “humoral and cellular immune response.” The vaccine candidate also showed an immune response in mice and pigs, according to information in a pre-print paper. <br>

              Outcomes: Preliminary results from the trial published in The Lancet showed the vaccine candidate had an “acceptable safety profile” with most patients demonstrating an antibody response after one dose and all patients showing a response after two doses. <br>

              Status: On 21 May, AstraZeneca announced it has received $1 billion in funding from the Biomedical Advanced Research and Development Authority (BARDA) for “development, production and delivery of the vaccine,” beginning in September 2020.
              </div>
            </div>
            </div>
            
                                      <!--Progress10-->
            <div class="row" style="margin-top: 10vh;">
                <div class="col-4">
                <div class="row">
                    <div class="col-4"></div>
                    <div class="col-8"> 
                    <p class="name"> Vaxine pty Ltd.</p> 
                    </div>
                </div>
                </div>
                <div class="col-8"> 
                 <div class="row">
                 <div class="col-9">
                <div class="progress">
                  <div class="progress-bar bg-danger" role="progressbar" style="width: 20%" aria-valuenow="15" aria-valuemin="0" aria-valuemax="100">Clinical</div>
                  <div class="progress-bar bg-info" role="progressbar" style="width: 20%" aria-valuenow="30" aria-valuemin="0" aria-valuemax="100">Phase I</div>
                  <div class="progress-bar bg-light" role="progressbar" style="width: 20%" aria-valuenow="20" aria-valuemin="0" aria-valuemax="100"></div>                  
                  <div class="progress-bar bg-light" role="progressbar" style="width: 20%" aria-valuenow="20" aria-valuemin="0" aria-valuemax="100"></div>                  
                  <div class="progress-bar bg-light" role="progressbar" style="width: 20%" aria-valuenow="20" aria-valuemin="0" aria-valuemax="100"></div>
                </div>
                </div>
                  <div class="col-3"></div>
                </div>
                </div>
            </div>
            
            <!--            Content10-->
            
            <div style="text-align: center;">
            <p>
                  <button class="btn btn-primary" type="button" data-toggle="collapse" data-target="#collapseExample10" aria-expanded="false" aria-controls="collapseExample">More info!
                  </button>
                    <a href="http://vaxine.net/" class="btn btn-warning">Take me there!</a>  
            </p>
            <div class="collapse" id="collapseExample10">
              <div class="card card-body" style="background-color: #13a5e4; color:white;">
              
              Background: Vaxine Pty Ltd. has developed a monovalent recombinant protein vaccine. <br>
 
                Study Design: A Phase 1 (NCT04453852) randomized, placebo controlled trial of 40 healthy adults aged 18-65 years who will receive either Covax-19 (25 μg of spike antigen plus 15 mg of Advax-2 adjuvant) or saline to assess generation of neutralizing antibodies to the spike proteins of SARS-CoV-2, as well as induction of T-cells against the spike proteins. Participants will receive two dose given three weeks apart.
              </div>
            </div>
            </div>
            
                                      <!--Progress11-->
            <div class="row" style="margin-top: 10vh;">
                <div class="col-4">
                <div class="row">
                    <div class="col-4"></div>
                    <div class="col-8"> 
                    <p class="name"> Zydus Cadila</p> 
                    </div>
                </div>
                </div>
                <div class="col-8"> 
                 <div class="row">
                 <div class="col-9">
                <div class="progress">
                  <div class="progress-bar bg-danger" role="progressbar" style="width: 20%" aria-valuenow="15" aria-valuemin="0" aria-valuemax="100">Clinical</div>
                  <div class="progress-bar bg-light" role="progressbar" style="width: 20%" aria-valuenow="30" aria-valuemin="0" aria-valuemax="100"></div>
                  <div class="progress-bar bg-light" role="progressbar" style="width: 20%" aria-valuenow="20" aria-valuemin="0" aria-valuemax="100"></div>                  
                  <div class="progress-bar bg-light" role="progressbar" style="width: 20%" aria-valuenow="20" aria-valuemin="0" aria-valuemax="100"></div>                  
                  <div class="progress-bar bg-light" role="progressbar" style="width: 20%" aria-valuenow="20" aria-valuemin="0" aria-valuemax="100"></div>
                </div>
                </div>
                  <div class="col-3"></div>
                </div>
                </div>
            </div>
            
            <!--            Content11-->
            
            <div style="text-align: center;">
            <p>
                  <button class="btn btn-primary" type="button" data-toggle="collapse" data-target="#collapseExample11" aria-expanded="false" aria-controls="collapseExample">More info!
                  </button>
                    <a href="https://zyduscadila.com/" class="btn btn-warning">Take me there!</a>  
            </p>
            <div class="collapse" id="collapseExample11">
              <div class="card card-body" style="background-color: #13a5e4; color:white;">
              Background: India’s Zydus Cadila is researching ZyCoV-D, a plasmid DNA vaccine candidates for COVID-19 that targets the viral entry membrane protein of the virus. The company has launched an adaptive Phase 1/2 dose escalation trial and plans to enroll about 1,000 healthy volunteers.
              </div>
            </div>
            </div>
            
                                      <!--Progress12-->
            <div class="row" style="margin-top: 10vh;">
                <div class="col-4">
                <div class="row">
                    <div class="col-4"></div>
                    <div class="col-8"> 
                    <p class="name"> Bharat Biotech.</p> 
                    </div>
                </div>
                </div>
                <div class="col-8"> 
                 <div class="row">
                 <div class="col-9">
                <div class="progress">
                  <div class="progress-bar bg-danger" role="progressbar" style="width: 20%" aria-valuenow="15" aria-valuemin="0" aria-valuemax="100">Clinical</div>
                  <div class="progress-bar bg-light" role="progressbar" style="width: 20%" aria-valuenow="30" aria-valuemin="0" aria-valuemax="100"></div>
                  <div class="progress-bar bg-light" role="progressbar" style="width: 20%" aria-valuenow="20" aria-valuemin="0" aria-valuemax="100"></div>                  
                  <div class="progress-bar bg-light" role="progressbar" style="width: 20%" aria-valuenow="20" aria-valuemin="0" aria-valuemax="100"></div>                  
                  <div class="progress-bar bg-light" role="progressbar" style="width: 20%" aria-valuenow="20" aria-valuemin="0" aria-valuemax="100"></div>
                </div>
                </div>
                  <div class="col-3"></div>
                </div>
                </div>
            </div>
            
            <!--            Content12-->
            
            <div style="text-align: center;">
            <p>
                  <button class="btn btn-primary" type="button" data-toggle="collapse" data-target="#collapseExample12" aria-expanded="false" aria-controls="collapseExample">More info!
                  </button>
                    <a href="https://www.bharatbiotech.com/covaxin.html" class="btn btn-warning">Take me there!</a>  
            </p>
            <div class="collapse" id="collapseExample12">
              <div class="card card-body" style="background-color: #13a5e4; color:white;">
              Background: Bharat Biotech, an Indian biotechnology company, is partnering with the National Institute of Virology to develop an inactivated vaccine candidate for COVID-19 called Covaxin. A Phase 1/2 trial of about 1,100 healthy participants is underway after approval by the Drug Controller General of India. In addition to Covaxin, Bharat Biotech is working on two other vaccine candidates: one with the University of Wisconsin–Madison and FluGen, and the other with Thomas Jefferson University. <br>

              Status: Early results in the first 50 people who received the vaccine candidate appear to be "encouraging," according to a comment from the trial's principal investigator.
              
              </div>
            </div>
    <br><br>
            </div>
                  
                   
                   
            
        </div>
        
        </main>
        
        <footer>
                 <h6> Copyrights &copy; Dive in Design. All rights reserved.</h6>
            <br>
        </footer>

        

        
    
    
    <!--    bootstrap-->
    <script src="https://code.jquery.com/jquery-3.5.1.slim.min.js" integrity="sha384-DfXdz2htPH0lsSSs5nCTpuj/zy4C+OGpamoFVy38MVBnE+IbbVYUew+OrCXaRkfj" crossorigin="anonymous"></script>
    <script src="https://cdn.jsdelivr.net/npm/popper.js@1.16.0/dist/umd/popper.min.js" integrity="sha384-Q6E9RHvbIyZFJoft+2mJbHaEWldlvI9IOYy5n3zV9zzTtmI3UksdQRVvoxMfooAo" crossorigin="anonymous"></script>
    <script src="https://stackpath.bootstrapcdn.com/bootstrap/4.5.0/js/bootstrap.min.js" integrity="sha384-OgVRvuATP1z7JjHLkuOU7Xw704+h835Lr+6QL9UvYjZE3Ipu6Tp75j7Bh/kR0JKI" crossorigin="anonymous"></script>

</body>

</html>
